Adriamycin and cyclophosphamide followed by tamoxifen, versus the combination of gonadotropin-releasing hormone analog and tamoxifen, in the treatment of premenopausal endocrine-responsive node-negative breast cancer.

Abstract

Abstract Abstract #1151 Purpose
 To compare the efficacy of adriamycin and cyclophosphamide (AC) followed by tamoxifen (AC->T) with gonadotropin-releasing hormone analog plus tamoxifen (GnRHa+T) in premenopausal women with hormone-response, node-negative breast cancer.
 Patients and Methods 
 We retrospectively reviewed the records of 587 premenopausal women with hormone- responsive, node-negative breast cancer. Of these, 269 were treated with AC->T, and 318 were treated with GnRHa (goserelin acetate 3.6 mg/kg or leuprorelin acetate 3.75 mg/kg every 28 days subcutaneously)+T. The main study outcome was disease-free survival (DFS).
 Results
 At a median follow-up time of 30 months, eight patients had relapsed and three had died. DFS did not differ between the AC->T and GnRHa+T groups. Of the three deaths, two were not related to breast cancer. The third patient, in the AC ->T group, died because of brain metastasis. GnRHa+T treatment had no effect on blood profile and did not cause the development of detrimental symptoms but decreased bone mineral density. The efficacy of leuprorelin was similar to that of goserelin.
 Conclusion 
 GnRHa +T and AC->T had comparable efficacy after 30 months of follow-up. The efficacy and tolerability of leuprorelin acetate was similar to that of goserelin. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 1151.